Tags : BioAtla

BeiGene Signs a Worldwide Co-Development and Commercialization Agreement with BioAtla

Shots: BioAtla to receive $20M upfront, $249M as WW development & regulatory milestones, commercial milestones and royalties in Beigene’s territory (Asia (ex-Japan), Australia and New Zealand). Beigene to get WW co-exclusive & exclusive development & commercialization rights respectively for BioAtla’ BA3071 in combination with Beigene’s tislelizumab Beigene to take care of all development & commercialization […]Read More